Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606426 | 0.95 | LMNA (0.36) | ELANELMNAGAAOPRM1PDK2 | |
| SCHEMBL2125191 | 0.89 | ELANE (0.46) | ELANEKMT2AATMLMNAOPRM1 | |
| SCHEMBL2604681 | 0.89 | ELANE (0.38) | ELANEKMT2AATMLMNAGAA | |
| SCHEMBL2606301 | 0.81 | LMNA (0.34) | LMNAGAA | |
| SCHEMBL2604683 | 0.81 | KMT2A (0.40) | ELANEKMT2AATMPDK2 | |
| SCHEMBL2604674 | 0.80 | PDK2 (0.39) | ELANEKMT2AATMPDK2 | |
| SCHEMBL2604686 | 0.79 | HTR7 (0.33) | ELANEKMT2AATMLMNAGAA | |
| SCHEMBL15339126 | 0.79 | ELANE (0.36) | ELANEKMT2AATMPOLBHTT | |
| SCHEMBL21266419 | 0.78 | ELANE (0.46) | ELANEKMT2AATMGAAPOLB | |
| SCHEMBL2604689 | 0.78 | PDK2 (0.38) | ELANEKMT2AATMPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | KLK3, PDE7A, FZD7 | ELANE 2411/4885KMT2A 3313/4885ATM 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.